Lowering Drug Pricing and Reducing OOP Cost

Together with 52  patient advocacy groups, we submitted a response to the U.S. Department of Health & Human Services (HHS) RFI on its Blueprint to Lower Drug Prices & Reduce OOP Costs on July 16, 2018. Our patients are our priority, and we want to be sure their needs are considered in future policy development.

Read our full letter to the Department of Health and Human Services online.

Making the Case for Women’s Health Research

Champions Janet Dennis and Florence Champagne and Dr. Eileen Hsich meet with Rep. Mary Gay…

Read More

Offices on Women’s Health

We’ve come a long way in our evolution of defining “women’s health” over the last…

Read More

Taking Stock of Heart Health Policy

If it wasn’t already high on the legislative agenda, health policy certainly took the spotlight…

Read More